Biocon Limited (BOM:532523)
India flag India · Delayed Price · Currency is INR
364.60
+4.00 (1.11%)
At close: Aug 7, 2025

Biocon Company Description

Biocon Limited, together with its subsidiaries, manufactures and sells biotechnology products and research services in India, the United States, Ireland, rest of the European Union, and internationally.

It operates through Generics, Biosimilars, and Research segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, multiple sclerosis, anti-fungal, anti-cancer, immunosuppressants, and specialty molecules; and biosimilars products consisting of pegfilgrastim, trastuzumab, bevacizumab, adalimumab, etanercept, ustekinumab, glargine, aspart, insulins, and aflibercept.

It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer goods, and agrochemical companies.

In addition, the company offers enzyme, biopharmaceutical, and medicinal goods; contract research and manufacturing services, and other research and development in the fields of pharmaceuticals, drug discovery, biotechnology pharmaceuticals, and medicinal sciences, etc.; clinical research; and business support and development, and marketing services.

Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.

Biocon Limited
CountryIndia
Founded1978
IndustryBiological Products, Except Diagnostic Substances
Employees16,315
CEOSiddharth Mittal

Contact Details

Address:
20th KM, Hosur Road
Bengaluru, Karnataka 560100
India
Phone91 80 2808 2808
Websitebiocon.com

Stock Details

Ticker Symbol532523
ExchangeBombay Stock Exchange
Fiscal YearApril - March
Reporting CurrencyINR
SIC Code2836

Key Executives

NamePosition
Siddharth MittalChief Executive Officer
Mukesh Kamath KChief Financial Officer
Arun GuptaChief Operating Officer
Saurabh PaliwalHead of Investor Relations